Top Qs
Timeline
Chat
Perspective
ASR-2001
Pharmaceutical compound From Wikipedia, the free encyclopedia
Remove ads
ASR-2001, also known as 2CB-5PrO or as 4-bromo-2-methoxy-5-propoxyphenethylamine, is a non-hallucinogenic serotonin receptor agonist of the phenethylamine, 2C, and TWEETIO families which is under development for the treatment of psychiatric disorders.[2][3][4][5][6][7] It is the TWEETIO analogue of 2C-B in which the 5-methoxy group is replaced with a 5-propoxy group.[5][8]
The drug is a non-hallucinogenic serotonin 5-HT2A receptor agonist and is orally active, highly potent, and has high selectivity over the serotonin 5-HT2B receptor (94-fold in terms of activational potency).[3][4][5][1][9][8] It is also a highly potent agonist of the serotonin 5-HT1B receptor, whereas its activity at the serotonin serotonin 5-HT1A receptor was very weak and its activity at the serotonin 5-HT2C receptor was not described.[8] ASR-2001 showed no significant activity at a variety of other sites, including other serotonin receptors and the monoamine transporters.[8] The drug is said to have low efficacy in terms of serotonin 5-HT2A receptor activation, and this is said to be responsible for its lack of hallucinogenic effects.[9]
According to its developers, ASR-2001 has no overt psychedelic effects, but instead produces a "focusing-type" "state of mental clarity" without the frank psychostimulant effects of drugs like amphetamine and methylphenidate.[3][4][1][9] It is said to affect mood, concentration, and focus, to not disturb but to potentially facilitate detailed work, and to capture the effects that are being sought with psychedelic microdosing but with less risk.[9][1] As an example of its better safety profile, there is a ceiling effect with ASR-2001 such that pushing the dose will not result in an accidental psychedelic experience.[9] In addition, the drug has strong selectivity over the toxic serotonin 5-HT2B receptor, in contrast to classical psychedelics like LSD and psilocybin.[9] ASR-2001 is said to have a dose range of 10 to 40 mg, an onset of 1 to 1.5 hours, and a duration of 8 to 10 hours.[1] Its psychoactive effects are described as "subtle".[1]
ASR-2001 is under development by Nicholas V. Cozzi and Paul F. Daley and colleagues at the Alexander Shulgin Research Institute (ASRI).[3][4][1][2] It was first described in 2023[1][3] and was patented in 2024.[5][8] As of early 2025, ASR-2001 is in the preclinical research stage of development.[7][2] Potential applications of ASR-2001 are said to include treatment of attention-deficit hyperactivity disorder (ADHD) and self-betterment in healthy individuals, depending on what regulatory agencies may allow.[9]
Remove ads
See also
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads